États-Unis · Plateformes & données · MarketBeat

ProKidney Targets Q2 2027 Phase III Readout as Rilparencel Enrollment Surpasses 500

Publié par MarketBeat · États-Unis il y a 1 h

ProKidney (NASDAQ:PROK) said it remains on track to report top-line results from the interim analysis of its Phase III PROACT 1 study in the second quarter of 2027, following…

Lire l'article complet sur MarketBeat Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.marketbeat.com)

ProKidney Targets Q2 2027 Phase III Readout as Rilparencel Enrollment Surpasses 500

À lire aussi

Can nVent Electric Become the Next Vertiv?

The real way to tell if Amazon’s AI spending is paying off

Top Performing Defensive Stocks

Earnings call transcript: Nebras Energy tops revenue estimates in Q3 2026

Gen Korean BBQ’s next chapter comes with wagyu, buffets and new names

Novartis Raises Guidance After Trial Setbacks Hit Profit

ProKidney Targets Q2 2027 Phase III Readout as Rilparencel Enrollment Surpasses 500

Partager

À lire aussi

Can nVent Electric Become the Next Vertiv?

The real way to tell if Amazon’s AI spending is paying off

Top Performing Defensive Stocks

Earnings call transcript: Nebras Energy tops revenue estimates in Q3 2026

Gen Korean BBQ’s next chapter comes with wagyu, buffets and new names

Novartis Raises Guidance After Trial Setbacks Hit Profit